



ATTORNEY DOCKET NO.: 0492479-0033 (MGH 2231)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Xudong, Huang  
Serial No.: 10/762,965  
Filing Date: January 22, 2004  
Title: Amyloid-Binding, Metal-Chelating Agents

Examiner:  
Art Unit:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (6 pages);
2. Information Disclosure Statement (6 pages);
3. Transmittal Letter (1 page)
4. Cited Art (82); and
5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,


  
Brenda Herschbach Jarrell, Ph.D.  
Registration No.: 39,223

CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 248-5000

Dated: 3/25/2004

3672918\_1.DOC

I hereby certify that this correspondence is being deposited  
with the United States Postal Service as first class mail in  
an envelope addressed to: Commissioner For Patents,  
P.O. Box 1450, Alexandria, VA 22313

on 3-26-04  




ATTORNEY DOCKET NO.: 0492479-0033 (MGH 2231)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Xudong, Huang                      Examiner:  
Serial No.: 10/762,965                      Art Unit:  
Filing Date: January 22, 2004  
Title: Amyloid-Binding, Metal-Chelating Agents

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

**Type of Statement**

The present Information Disclosure Statement is:

- [X] An *original* Information Disclosure Statement; or  
[ ] A *supplemental* Information Disclosure Statement.

<b>Certificate of Mailing</b>	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
3/26/04	<i>Sandra Saccoccia</i>
Date	Signature
Sandra Saccoccia	
Typed or Printed Name of person signing certificate	

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- ☒ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
- ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
- ☐ Before the mailing of a first Office action on the merits; or
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- ☐ Certifies that *either*:
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

☐ Includes herewith the fee set forth in § 1.17(p).

### Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;
- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, for which an English language abstract is submitted.

[ ] Does contain non-English language citations which were cited on an International Search Report (a copy of which is enclosed herewith).

[ ] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).



Respectfully submitted,

---

Brenda Herschbach Jarrell, Ph.D.  
Registration No. 39,223

CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, Massachusetts 02109  
(617) 248-5000  
(617) 248-4000

Dated: \_\_\_\_\_

3672585

<b>FORM PTO-1449</b> (REV. 8-83) <b>89 P E</b> <b>MAR 29 2004</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		U.S. Department of Commerce Patent and Trademark Office  Atty. Docket: 0492479-0033  In Re Application No.: 10/762,965  Applicant: Xudong, Huang  Filing Date: January 22, 2004  Group:			
<b>U.S. PATENT DOCUMENTS</b>					
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
<b>U.S. PATENT APPLICATIONS</b>					
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
<b>OTHER DOCUMENTS</b>					
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Arnold, F., "Metal-Affinity Separations: A New Dimension in Protein Processing", <i>Bio/Technology</i> , <b>9</b> : 151-156.				
✓	Atwood, et al., "Role of Free Radicals and Metal Ions in the Pathogenesis of Alzheimer's Disease", Pages 309-364				
	Atwood, et al., "Dramatic Aggregation of Alzheimer A $\beta$ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis", <i>The Journal of Biological Chemistry</i> , <b>273</b> (21): 12817-12826, 1998.				
	Bartzokis, et al., "MR Evaluation of Age-Related Increase of Brain Iron in Young Adult and Older Normal Males", <i>Magnetic Resonance Imaging</i> , <b>15</b> (1): 29-35, 1997.				
	Bielski, B., "Fast Kinetic Studies of Dioxygen-Derived Species and Their Metal Complexes", <i>Phil Trans R. Soc. Lond. B</i> , <b>311</b> : 473-482, 1985.				
	Biewenga, et al., "The Pharmacology of the Antioxidant Lipoic Acid", <i>Gen. Pharmac.</i> <b>29</b> (3): 315-331, 1997.				
	Brewer, et al., "Survival and Growth of Hippocampal Neurons in Defined Medium at Low Density: Advantages of a Sandwich Culture Technique or Low Oxygen", <i>Brain Research</i> , <b>494</b> : 65-74, 1989.				
	Brookmeyer, et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset", <i>American Journal of Public Health</i> , <b>88</b> (9): 1337-1342, 1998.				
	Burns, et al., "The Specificity of the Staining of Amyloid Deposits with Thioflavine T", <i>J.</i>				



INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Xudong, Huang

Filing Date:  
January 22, 2004

Group:

*Path. Bact.* **94**: 337-344, 1967.

Bush, et al., "Modulation of A $\beta$  Adhesiveness and Secretase Site Cleavage by Zinc", *The Journal of Biological Chemistry*, **269**(16): 12152-12158, 1994.

Bush, et al., "Rapid Induction of Alzheimer A $\beta$  Amyloid Formation by Zinc", *Science*, **265**, 1464-1467, 1994.

Caravan, et al., "Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications", *Chem. Rev.* **99**: 2293-2352, 1999.

Carter, et al., "A Model for Structure-Dependent Binding of Congo Red to Alzheimer  $\beta$ -Amyloid Fibrils", *Neurobiology of Aging*, **19**(1): 37-40, 1998.

Cerniglia, et al., "Metabolism of Benzidine and Benzidine-Congener Based Dyes by Human, Monkey and Rat Intestinal Bacteria", *Biochemical and Biophysical Research Communications*, **107**(4): 1224-1229, 1982.

Cerniglia, et al., "Metabolism of Azo Dyes Derived from Benzidine, 3,3'-Dimethyl-Benzidine and 3,3'-Dimethoxybenzidine to Potentially Carcinogenic Aromatic Amines by Intestinal Bacteria", *Carcinogenesis*, **3**(11): 1255-1260, 1982.

Cherny, et al., "Aqueous Dissolution of Alzheimer's Disease A $\beta$  Amyloid Deposits by Biometal Depletion", *The Journal of Biological Chemistry*, **274**(33): 23223-23228, 1999.

Cherny, et al., "Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits  $\beta$ -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice", *Neuron*, **30**: 665-676, 2001.

Connor, et al., "Regional Distribution of Iron and Iron-Regulatory Proteins in the Brain in Aging and Alzheimer's Disease", *Journal of Neuroscience Research*, **31**: 327-335, 1992.

Cornett, et al., "Imbalances of Trace Elements Related to Oxidative Damage in Alzheimer's Disease Brain", *NeuroToxicology*, **19**(3): 339-346, 1998.

Cuajungco, et al., "Evidence that the  $\beta$ -Amyloid Plaques of Alzheimer's Disease Represent the Redox-Silencing and Entombment of A $\beta$  by Zinc", *The Journal of Biological Chemistry*, **275**(26): 19439-19442, 2000.

Deibel, et al., "Copper, Iron, and Zinc Imbalances in Severely Degenerated Brain Regions in Alzheimer's Disease: Possible Relation to Oxidative Stress", *Journal of the Neurological Sciences*, **143**: 137-142, 1996.

Del Corso, et al., "Blood Zinc, Copper and Magnesium in Aging", *Panminerva Med.*, **42**: 273-277, 2000.

Dezutter, et al., "<sup>99m</sup>Tc-MAMA-Chrysamine G, A Probe for Beta-Amyloid Protein of Alzheimer's Disease", *European Journal of Nuclear Medicine*, **26**(11): 1392-1399, 1999.

Drayer, et al., "MRI of Brain Iron", *AJR*, **147**: 103-110, 1986.

Ernst, et al., "Cognitive Function and the Costs of Alzheimer Disease", *Arch Neurol.*, **54**: 687-693, 1997.

Evans, et al., "Prevalence of Alzheimer's Disease in a Community Population of Older Persons", *JAMA*, **262**(18): 2551-2556, 1989.

Atty. Docket:  
0492479-0033

In Re Application No.:  
10/762,965

Applicant: Xudong, Huang

Filing Date:  
January 22, 2004

Group:

Farr, et al., "The Antioxidants  $\alpha$ -Lipoic Acid and N-Acetylcysteine Reverse Memory Impairment and Brain Oxidative Stress in Aged SAMP8 Mice", *Journal of Neurochemistry*, **84**: 1173-1183, 2003.

Fonte, et al., "The Severity of Cortical Alzheimer's Type Changes is Positively Correlated with Increased Amyloid- $\beta$  Levels: Resolubilization of Amyloid- $\beta$  with Transition Metal Ion Chelators", *Journal of Alzheimer's Disease*, **3**: 209-219, 2001.

✓ Friman, et al., "Amyloidosis", *Current Opinion in Rheumatology*, **8**: 62-71, 1996.

Fritz, et al., "Synthesis and Biological Evaluation of Tc-99m N,N'-Bis(Mercaptoacetyl)-2,3-Diaminopropanoate: A Potential Replacement for [ $^{131}$ I]o-Iodohippurate", *J. Nucl. Med.* **23**: 592-598, 1982.

✓ Gabbita, et al., "Increased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease", *Journal of Neurochemistry*, **71**(5): 2034-2040, 1998.

Guntern, et al., "An Improved Thioflavine S Method for Staining Neurofibrillary Tangles and Senile Plaques in Alzheimer's Disease", *Experientia*, **48**: 8-10, 1992.

Gutteridge, et al., "Copper Salt-Dependent Hydroxyl Radical Formation", *Biochimica et Biophysica Acta*, **759**: 38-41, 1983.

Han, et al., "Quantitation of Hydrogen Peroxide Using Tris(2-Carboxyethyl)Phosphine", *Analytical Biochemistry*, **234**: 107-109, 1996.

Hilbich, et al., "Substitutions of Hydrophobic Amino Acids Reduce the Amyloidogenicity of Alzheimer's Disease  $\beta$ A4 Peptides", *J. Mol. Biol.* **228**: 460-473, 1992.

Huang, et al., "Cu(II) Potentiation of Alzheimer A $\beta$  Neurotoxicity", *The Journal of Biological Chemistry*, **274**(52): 37111-37116, 1999.

Huang, et al., "The A $\beta$  Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide Through Metal Ion Reduction", *Biochemistry*, **38**(24): 7609-7616, 1999.

Huang, et al., "Zinc-Induced Alzheimer's A $\beta$ 1-40 Aggregation is a Mediated by Conformational Factors", *The Journal of Biological Chemistry*, **272**(42): 26464-26470, 1997.

Hüber, et al., "Fluorescently Detectable Magnetic Resonance Imaging Agents", *Bioconjugate Chem.*, **9**: 242-249, 1998.

Ida, et al., "Analysis of Heterogeneous  $\beta$ A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", *The Journal of Biological Chemistry*, **271**(37): 22906-22914, 1996.

Johnson, et al., "Synthesis of a Ligand Based Upon a New Entry into the 3-Hydroxy-N-Alkyl-2(1H)-Pyridinone Ring System and Thermodynamic Evaluation of Its Gadolinium Complex", *Inorg. Chem.* **39**: 2652-2660, 2000.

Katzman, et al., "Education and the Prevalence of Dementia and Alzheimer's Disease", *Neurology*, **43**: 13-20, 1993.

Kelenyi, G., "On the Histochemistry of Azo Group-Free Thiazole Dyes" *The Journal of Histochemistry and Cytochemistry*, **15**(3): 172-180, 1967.

INFORMATIONAL DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Xudong, Huang

Filing Date:  
January 22, 2004

Group:

- |   |  |
|---|--|
|   | Kelly, J., "The Environmental Dependency of Protein Folding Best Explains Prion and Amyloid Diseases", <i>Proc. Natl. Acad. Sci. USA</i> , <b>95</b> : 930-932, 1998.  |
|   | Kelly, J., "The Environmental Dependency of Protein Folding Best Explains Prion and Amyloid Diseases", <i>Proc. Natl. Acad. Sci., USA</i> , <b>95</b> : 930-932, 1998.                                       |
|   | Klunk, et al., "Development of Small Molecule Probes for the Beta-Amyloid Protein of Alzheimer's Disease", <i>Neurobiology of Aging</i> , <b>15</b> (6): 691-698, 1994.                                      |
|   | Klunk, W., "Biological Markers of Alzheimer's Disease", <i>Neurobiology of Aging</i> , <b>19</b> (2): 145-147, 1998.   |
|   | Klunk, et al., "Uncharged Thioflavin-T Derivatives Bind to Amyloid-Beta Protein with High Affinity and Readily Enter the Brain", <i>Life Sciences</i> , <b>69</b> : 1471-1484, 2001.                         |
|   | Koh, et al., "β-Amyloid Protein Increases the Vulnerability of Cultured Cortical Neurons to Excitotoxic Damage", <i>Brain Research</i> , <b>533</b> : 315-320, 1990.   |
|   | Konings, et al., "Gadolinium Complexation by a New DTPA-Amide Ligand. Amid Oxygen Coordination", <i>Inorg. Chem.</i> <b>29</b> : 1488-1491, 1990.  |
|   | Kuhn, W., "NMR Microscopy – Fundamentals, Limits and Possible Applications", <i>Angew. Chem. Int. Ed. Engl.</i> , <b>29</b> : 1-19, 1990.  |
|   | Landers, et al., "Determination of Serum Copper and Iron in a Single Small Sample", <b>29</b> : 590-592, 1958.   |
|   | Levine, "Quantification of β-Sheet Amyloid Fibril Structures with Thioflavin T", <i>Methods in Enzymology</i> , <b>309</b> : 274-284, 1999.  |
|   | Loeffler, et al., "Increased Regional Brain Concentrations of Ceruloplasmin in Neurodegenerative Disorders", <i>Brain Research</i> , <b>738</b> : 265-274, 1996.   |
|   | Lovell, et al., "Copper, Iron and Zinc in Alzheimer's Disease Senile Plaques", <i>Journal of the Neurological Sciences</i> , <b>158</b> : 47-52, 1998.   |
|   | Magerstadt, et al., "Gd(DOTA): An Alternative to Gd(GTPA) as a T <sub>1,2</sub> Relaxation Agent for NMR Imaging or Spectroscopy", <i>Magnetic Resonance in Medicine</i> , <b>3</b> : 808-812, 1986.         |
| ↓ | Mann, et al., "The Neuropathology of Alzheimer's Disease: A Review with Pathogenetic, Aetiological and Therapeutic Considerations", <i>Mechanisms of Ageing and Development</i> , <b>31</b> : 213-255, 1985. |
|   | Markesbery, W., "Oxidative Stress Hypothesis in Alzheimer's Disease", <i>Free Radical Biology &amp; Medicine</i> , <b>23</b> (1): 134-147, 1997.   |
|   | Martins, et al., "Increased Cerebral Glucose-6-Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress", <i>Journal of Neurochemistry</i> , <b>46</b> : 1042-1045, 1986.        |
|   | Masters, et al., "Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome", <i>Proc. Natl. Acad. Sci. USA</i> , <b>82</b> : 4245-4249, 1985.  |
|   | Meyer, et al., "Advances in Macrocyclic Gadolinium Complexes as Magnetic Resonance Imaging Contrasts Agents", <i>Invest. Radiol.</i> <b>25</b> : S53-S55, 1990.  |

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Xudong, Huang

Filing Date:  
January 22, 2004

Group:

McKhann, et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease", *Neurology*, **34**: 939-944, 1984.

Merlini, et al., "Interaction of the Anthracycline 4'-Iodo-4'-Deoxydoxorubicin with Amyloid Fibrils: Inhibition of Amyloidogenesis", *Proc. Natl. Acad. Sci. USA*, **92**: 2959-2963, 1995.

Mirra, et al., "Neuropathologic Assessment of Alzheimer's Disease", *Neurology*, **49**(3): S14-S16, 1997.

Moats, et al., "A "Smart" Magnetic Resonance Imaging Agent That Reports on Specific Enzymatic Activity", *Angew Chem. Int. Ed. Engl.* **36**(7): 726-728, 1997.

Moini, et al., "Antioxidant and Prooxidant Activities of  $\alpha$ -Lipoic Acid and Dihydrolipoic Acid", *Toxicology and Applied Pharmacology*, **182**: 84-90, 2002.

Morgan, et al., "Summary of the National Toxicology Program Benzidine Dye Initiative", *Environ Health Perspect*, **102**(2): 63-78, 1994.

Packer, et al., "Alpha-Lipoic Acid as a Biological Antioxidant", *Free Radical Biology & Medicine*, **19**(2): 227-250, 1995.

Pappolla, et al., "Immunohistochemical Evidence of Antioxidant Stress in Alzheimer's Disease", *American Journal of Pathology*, **140**(3): 621-628, 1992.

Rogers, et al., "Translation of the Alzheimer Amyloid Precursor Protein mRNA is Up-Regulated by Interleukin-1 Through 5'-Untranslated Region Sequences", *The Journal of Biological Chemistry*, **274**(10): 6421-6431, 1999.

Rogers, et al., "Alzheimer's Disease Drug Discovery Targeted to the APP mRNA 5'-Untranslated Region", *Journal of Molecular Neuroscience*, **19**: 77-82, 2002.

Rogers, et al., "An Iron-Responsive Element Type II in the 5'-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript", *The Journal of Biological Chemistry*, **277**(47): 45518-45528, 2002.

Sayre, et al., "In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer's Disease: A Central Role for Bound Transition Metals", *Journal of Neurochemistry*, **74**: 270-279, 2000.

Shi, et al., "Antitumor Benzothiazoles. 3.<sup>1</sup> Synthesis of 2-(4-Aminophenyl)Benzothiazoles and Evaluation of Their Activities Against Breast Cancer Cell Lines in *Vitro* and *In Vivo*. *J. Med. Chem.* **39**: 3375-3384, 1996.

Skovronsky, et al., "In Vivo Detection of Amyloid Plaques in a Mouse Model of Alzheimer's Disease", *PNAS*, **97**(13): 7609-7614, 2000.

Smith, et al., "Iron Accumulation in Alzheimer Disease is a Source of Redox-Generated Free Radicals", *Proc. Natl. Acad. Sci. USA*, **94**: 9866-9868, 1997.

Tubis, et al., "The Preparation and Use of Radioiodinated Congo Red in Detecting Amyloidosis", *Journal of the American Pharmaceutical Association*, **49**(7): 422-425, 1960.

Tubis, et al., "The Use of Radioiodinated Congo Red in the Study of Amyloidosis", Pages 25-38.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Xudong, Huang

Filing Date:  
January 22, 2004

Group:

Van Leeuwen, et al., "Frameshift Mutants of  $\beta$  Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down :Patients", *Science*, **279**:242-247, 1998.

Yankner, et al., "Neurotrophic and Neurotoxic Effects of Amyloid  $\beta$  Protein: Reversal by Tachykinin Neuropeptides", *Science*, **250**: 279-282, 1990.

Zhen, et al., "Synthesis and Amyloid Binding Properties of Rhenium Complexes: Preliminary Progress Toward a Reagent for SPECT Imaging of Alzheimer's Disease Brain", *J. Med. Chem.* **42**: 2805-2815, 1999.

Zhuang, et al., "Radioiodinated Styrylbenzenes and Thioflavins as Probes for Amyloid Aggregates", *J. Med. Chem.* **44**: 1905-1914, 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.